Review ArticlesThe Basis and Rational Use of Molecular Genetic Testing in Mature B-cell LymphomasRoullet, Michele MD*; Bagg, Adam MD†Author Information *Pathology Sciences Medical Group/Eastern Virginia Medical School, Norfolk, VA †Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA A.B. is supported in part by a SCOR grant from the Leukemia and Lymphoma Society of America. Reprints: Adam Bagg, MD, Pathology and Laboratory Medicine, University of Pennsylvania, 7.103 Founders Pavilion, 3400 Spruce Street, Philadelphia, PA 19104-4283 (e-mail: [email protected]). Advances in Anatomic Pathology: September 2010 - Volume 17 - Issue 5 - p 333-358 doi: 10.1097/PAP.0b013e3181ec7466 Buy Metrics Abstract An increasing number of neoplasms are associated with variably specific genetic abnormalities. This is best exemplified by hematological malignancies, in which there is a growing list of entities that are defined by their genetic lesion(s); this is not (yet) the case in mature B-cell lymphomas. However, enhanced insights into the pathogenesis of this large and diverse group of lymphomas have emerged with the ongoing unraveling of a plethora of fascinating genetic abnormalities. The purpose of this review is to synthesize well-recognized data and nascent discoveries in our understanding of the genetic basis of a spectrum of mature B-cell lymphomas, and how this may be applied to contemporary clinical practice. Despite the explosion of new and exciting knowledge in this arena, with the potential for enhanced diagnostic and prognostic strategies, it is essential to remain cognizant of the limitations (and complexity) of genetic investigations, so that assays can be developed and used both judiciously and rationally. © 2010 Lippincott Williams & Wilkins, Inc.